Education
About Us
Working with TipRanks
Follow Us
Palisade Bio (PALI)
NASDAQ:PALI
PALI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.60 - $4.32
Previous CloseN/A
Volume307.14K
Average Volume (3M)665.47K
Market Cap
$5.95M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 19, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding4,795,646
10 Day Avg. Volume1,715,669
30 Day Avg. Volume665,471
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.00Price Target Upside61.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Development StrategyPlans to initiate a Phase 1b trial and file an IND for a Phase 2 study indicate a clear development strategy for PALI-2108.
PharmacokineticsThe pharmacokinetic profile of PALI-2108 suggests it could be dosed once daily due to its extended release and low systemic exposure.
Safety ProfilePALI-2108 was found to be safe and well-tolerated in the Phase 1a trial, with no serious adverse events reported.
Bears Say
Financing ConcernsPalisade Bio will require another financing following the data, which may be more dilutive given the current market dynamics.
Price TargetThe analyst's recommendation includes a lower 12-month price target due to expected dilution from future financing needs.
Palisade Bio News
PALI FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was $0.60 and its highest was $4.32 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is $5.95M.
When is Palisade Bio’s upcoming earnings report date?
Palisade Bio’s upcoming earnings report date is Aug 19, 2025 which is in 20 days.
How were Palisade Bio’s earnings last quarter?
Currently, no data Available
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate is -0.55.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 4,795,646 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in PALI
Company Description
Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Palisade Bio (PALI) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
PALI Stock 12 Month Forecast
Average Price Target
$2.00
▲(61.29%Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Quoin Pharmaceuticals
―
Artelo Biosciences
―
Galecto
―
SciSparc Ltd.
―
Ownership Overview
0.46% Insiders
0.30% Mutual Funds
3.63% Other Institutional Investors
95.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---